IONTAS Signs Collaboration Agreement With LG Chem, Ltd. to Identify Therapeutic Oncology Leads
Dr Neil Butt, CBO of IONTAS, said: “This new agreement marks IONTAS’ expansion into the Asian market, and we are delighted to have been selected by LG Chem, Ltd., after a rigorous diligence process. The application of our proprietary technologies will assist LG Chem, Ltd. in expanding its current therapeutic pipeline by generating leads against pre-defined specifications agreed at the project outset.”
Dr Myung Jin Kim, Executive Vice President / R&D Leader, Life Sciences R&D of LG Chem, Ltd., said: “IONTAS was selected because of its robust track record and technical know-how. We feel confident this collaboration will result in a strong panel of therapeutic leads which will help develop our oncology pipeline.”
Dr Neil Butt and Dr Mike Dyson, CTO of IONTAS, will attend the 2018 BIO International Convention (Boston, MA) from June 4 – 7 and Dr John McCafferty, CEO and Founder of IONTAS, will be at Antibody Engineering and Therapeutics Europe (Amsterdam, NL) from 5 – 7 June.
For further information, please visit https://www.iontas.co.uk/technologies/
For a high-resolution image please contact firstname.lastname@example.org